AlphaYou
Overview
Key stats
Fundamentals Sep 12- Open
- $522.10
- 52-wk high
- $560.25
- High
- $522.10
- 52-wk low
- $374.17
- Low
- $511.81
- Prev close
- $514.56
- Mkt cap
- $130.56B
- P/E
- 30.0x
- Volume
- 818.9K
- Fwd P/E
- 24.0x
- Beta
- 0.32
- P/S
- 10.4x
- P/B
- 6.4x
- Profit margin
- +35.0%
- Op margin
- +38.1%
- ROE
- +23.5%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 1.2% above what analysts expected.
Earnings per share
$4.15 expected
Revenue
$3.22B expected
Company adjusted EPS
From the company's release
The company and the analyst consensus count earnings differently, so the two figures differ. The comparison above uses the analyst basis.
GAAP EPS was $4.31 and adjusted EPS was $4.73. The adjusted figure is comparable to consensus.
FY2026 guidance
$13.10B to $13.20B
No comparable estimate
Reports Nov 2, 2026, in 50 days
EPS expected
-$29.56 to $5.18
Revenue expected
15 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $3.08B | $3.23B | $2.99B | $3.33B |
| Cost of what it sold | $414.8M | $466.0M | $392.8M | $489.2M |
| Gross profit | $2.66B | $2.76B | $2.59B | $2.84B |
| What it spent | ||||
| Research and development | $1.03B | $973.7M | $961.6M | $993.8M |
| Sales and admin | $445.1M | $487.0M | $493.7M | $582.2M |
| Other operating costs | — | — | — | $21.8M |
| Total operating expenses | $1.48B | $1.46B | $1.46B | $1.60B |
| What was left | ||||
| Operating profit | $1.19B | $1.30B | $1.14B | $1.25B |
| Interest on debt | $3.3M | $3.3M | — | — |
| Profit before tax | $1.30B | $1.33B | $1.25B | $1.39B |
| Tax | $215.9M | $139.9M | $221.5M | $292.0M |
| Net profit | $1.08B | $1.19B | $1.03B | $1.10B |
| EBITDA | $1.36B | $1.39B | $1.31B | $1.39B |
Technicals
Price structure
This stock's price action is mixed, and looks oversold after a sharp drop.
Trend
Mixed
45 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Vertex at cantor healthcare conference: diversification and pipeline push
BullishSep 10Frazier Life Sciences nets $1.1B in long-running fund aimed at small, midsize biotechs
Leans bullishSep 10Vertex at Wells Fargo healthcare conference: renal pipeline takes center stage
BullishSep 10Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock
BullishSep 8Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock
BullishSep 8CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
NeutralSep 8Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights
Leans bearishSep 8Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)
BullishSep 8
Macro
21 macro signals shaping VRTX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results